-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

907.O2.6 907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes

Symposia: Outcomes Research: Plasma Cell Disorders Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Research, Clinical Practice (Health Services and Quality), Elderly, Bispecific Antibody Therapy, Plasma Cell Disorders, Clinical Research, Health outcomes research, Supportive Care, Education, Health disparities research, Diseases, Therapy sequence, Immune Disorders, Immunodeficiency, Patient-reported outcomes, Treatment Considerations, Real-world evidence, Biological therapies, Lymphoid Malignancies, Adverse Events, Registries, Study Population, Human
Sunday, December 8, 2024: 4:30 PM-6:00 PM
San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Moderators:
Srinivas Devarakonda, MD, The Ohio State University Comprehensive Cancer Center and Nadine Abdallah, MD, Mayo Clinic
Disclosures:
No relevant conflicts of interest to declare.
Frailty and symptom assessment are critical but oft ignored part of the myeloma evaluation and treatment. These abstracts will review new frailty models, assessments and interventions.
4:30 PM

Imran Haider, MSc.1*, Darryl P. Leong, MBBS, MPH, PhD2,3*, Martha L Louzada, MD, MSc4,5, Arleigh McCurdy, MD6, Gregory R Pond, PhD7*, Ruthanne Cameron8*, Mohammed Aljama, MBBS, FRCPC9*, Alissa Visram, MD, MPH10, Tanya M. Wildes, MD, MSc11 and Hira Mian, MD12

1Royal College of Surgeons in Ireland, Dublin, Ireland
2Population Health Research Institute (PHRI), Hamilton, ON, Canada
3Department of Medicine, McMaster University, Hamilton, ON, Canada
4London Health Sciences Centre, London, ON, Canada
5London Regional Cancer Center, London, ON, Canada
6The Ottawa Hospital, Ottawa, ON, Canada
7Department of Oncology, McMaster University, Hamilton, ON, CAN
8Department of Oncology, McMaster University, Canada, Hamilton, ON, Canada
9Department of Oncology, McMaster University, Hamilton, Canada
10Division of Hematology, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
11University of Nebraska Medical Center, Omaha, NE
12McMaster University, Hamilton, ON, Canada

4:45 PM

Hira Mian, MD1, Carlyn Rose Tan, MD2, Sireesha Asoori, MBBS, MPH3*, Rakesh Popat4, Nadine Abdallah, MD5, Saurabh Chhabra, MD6, Ricardo D. Parrondo, MD7, Gregory R Pond, PhD8*, Thomas Martin, MD3, Brian G.M. Durie9 and Yi Lin, MD, PhD10

1McMaster University, Hamilton, ON, Canada
2Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
3University of California, San Francisco, CA
4Research department of Haematology, University College London Cancer Institute, London, United Kingdom
5Mayo Clinic, Rochester, MN
6Mayo Clinic Arizona, Phoenix, AZ
7Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL
8Department of Oncology, McMaster University, Hamilton, ON, CAN
9Cedars-Sinai Medical Center, Los Angeles, CA
10Division of Hematology, Mayo Clinic, Rochester, MN

5:00 PM

Janine M. Joseph, MS, MBA1*, Michaela Hillengass1*, Bryan J. Wittmeyer, MS, PT2*, Carolyn A. Miller, DPT2*, Hillary M. Jacobson, DPT2*, Kirsten B. Moysich, PhD, MS1*, Rikki A. Cannioto, PhD, EdD1* and Jens Hillengass, MD, PhD3

1Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY
2Physical Therapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY
3Department of Medicine - Myeloma, Roswell Park, Buffalo, NY

5:15 PM

Jorge Arturo Hurtado Martinez, MD1*, Felipe Flores Quiroz, MD1*, Jennifer M. Ahlstrom, BA1*, Rafael Fonseca, MD2, Julie R. Strain3*, Laura Iadeluca, PhD3*, Rachel M Jensen, BS1*, Cynthia Chmielewski1*, Saad Z. Usmani, MD4 and Jay R. Hydren, PhD1

1HealthTree Foundation, Lehi, UT
2Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ
3GlaxoSmithKline plc, Durham, NC
4Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

5:30 PM

Elizabeth K. O'Donnell, MD1, Thais Gift, PharmD2*, Zaid Yousif, PharmD3*, Lynn Huynh, MPH4*, Raj Desai, PhD4*, Gregory Belsky5*, Yichuan Hsieh, PhD5,6*, Nikhil Khandelwal, PhD2*, Mei Sheng Duh, MPH4, Shawn Murphy, MD5,6,7* and Marie Sanchirico, PhD2*

1Dana-Farber Cancer Institute, Boston, MA
2Takeda Pharmaceuticals USA, Inc., Lexington, MA
3Division of Clinical Pharmacy, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA
4Analysis Group, Inc., Boston, MA
5Mass General Brigham, Research Information Science & Computing, Somerville, MA
6Harvard Medical School, Boston, MA
7Neurology, Massachusetts General Hospital, Boston, MA

5:45 PM

Nora Grieb1,2*, Alexander Oeser, PhD2*, Maximilian Ferle3*, Franziska Hanke4*, Sarah Flossdorf5*, Sandra Sauer, MD6*, Hartmut Goldschmidt, MD7, Carsten Müller-Tidow, MD7*, Hans Salwender, MD8*, Roland Fenk, MD, PhD9*, Monika Engelhardt, MD10, Robert Zeiser, MD11, Vladan Vucinic, MD12*, Georg-Nikolaus Franke, MD13*, Igor Wolfgang Blau, MD, PhD14*, Daniel Teschner, MD15,16*, Hermann Einsele, MD17, Christoph Richard Kimmich, MD18*, Miriam Kull, MD19*, Britta Besemer, MD20*, Nico Gagelmann, M.D.21*, Nicolaus Kröger, MD4,22*, Thomas Neumuth, PhD23*, Uwe Platzbecker, MD24 and Maximilian Merz, MD24

1Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany
2Innovation Center Computer Assisted Surgery (ICCAS), University of Leipzig, Leipzig, Germany
3Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI), Leipzig University, Leipzig, AL, Germany
4German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), Ulm, Germany
5Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany
6Heidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
7Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
8Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St. Georg, Hamburg, Germany
9Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany
10Department of Medicine I, Faculty of Medicine, Medical Centre, University Hospital Freiburg, Freiburg Im Breisgau, DEU
11University of Freiburg, Faculty of Medicine, Albert Ludwigs University (ALU), Freiburg, Germany, Freiburg, Germany, Freiburg, Germany
12Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Saxony, Germany
13Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Leipzig Medical Center, Leipzig, Germany
14Medical Clinic, Charité University Medicine Berlin, Berlin, Germany
15Department of Medicine 3, University Hospital Mainz, Mainz, DEU
16Division of Hematology, University Hospital of Wurzburg, Wurzburg, Germany, Würzburg, Germany
17Division of Hematology, University Hospital of Wurzburg, Wurzburg, Germany, Würzburg, DEU
18Department of Oncology and Hematology, University Clinic Oldenburg, Oldenburg, Lower Saxony, DEU
19Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
20Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany
21Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
22University Medical Center Hamburg, Hamburg, Germany
23Innovation Center Computer Assisted Surgery (ICCAS), Universität Leipzig, Leipzig, Germany, Leipzig, Germany
24Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany

*signifies non-member of ASH